CompletedPHASE1, PHASE2NCT01962103
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Studying Dermatofibrosarcoma protuberans
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Ileana Elias, M.D.Celgene Corporation
- Intervention
- nab-paclitaxel(drug)
- Enrollment
- 107 enrolled
- Eligibility
- 24 years · All sexes
- Timeline
- 2013 – 2018
Study locations (20)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Columbia University Medical Center, New York, New York, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
- Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center, Lyon, France
- Hopital d'Enfants, CHU Nancy, Nancy, France
- Institut Curie, Paris, France
- Institut Gustave Roussy, Villejuif, France
- Azienda Ospedaliera Universitaria Meyer, Florence, Italy
- Children's Hospital Largo, Genova, Italy
- Istituto Nazionale Tumori, Milan, Italy
- Clinica di Oncoematologia, Padua, Italy
- Policlinico Agostino Gemelli, Rome, Italy
- l'Azienda Ospedaliera Regina Margherita - Sant Anna, Torino, Italy
- Hospital Universitario Vall D Hebron, Barcelona, Spain
- Hospital Sant Joan de Deu, Barcelona, Spain
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01962103 on ClinicalTrials.gov